Trial Profile

A global Phase 2b study evaluating GSBR-1290 in type 2 diabetes patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 22 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aleniglipron (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use

Most Recent Events

18 Dec 2023 According to a Structure Therapeutics media release, Phase 2 study in T2DM is planned for the second half of 2024 to optimize the efficacy and tolerability of GSBR-1290 in this patient population.
29 Sep 2023 According to a Structure Therapeutics media release, this study is expected to include approximately 500 individuals across the United States, Europe and Japan.
02 Jun 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com